1.	Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery Phase: Phase IV Type: Supportive care Status: Completed Age: 65 and under Sponsor: Other Protocol IDs: IWK-4298-2008, NCT00785382
2.	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Phase: Phase IV Type: Supportive care, Treatment Status: Closed Age: 35 to 90 Sponsor: Other Protocol IDs: 047838, NCT00805701
3.	Modafinil for the Treatment of Fatigue in Lung Cancer V1.0 Phase: Phase IV Type: Supportive care Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: Modafinil/lung/01, NCT00829322
4.	Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 40 to 75 Sponsor: Other Protocol IDs: Hamamatsu 18-66, NCT00752115
5.	Adjuvant Pazopanib in Stage I NSCLC Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: IFCT-0703, Eudract : 2008-004897-41, NCT00775307
6.	Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: ABC-03 09/0193, NCT00939848
7.	S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000306449, U10CA032102, S0232, SWOG-S0232, NCT00064038
8.	Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02978, E2603, U10CA021115, CDR0000423315, ECOG-E2603, NCT00110019
9.	Phase III Randomized Study of Cytarabine With Versus Without VNP40101M in Patients With Acute Myeloid Leukemia in First Relapse. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-037, NCT00112554
10.	Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000471238, NCCTG-N04C7, N04C7, NCT00316914
11.	Phase III Randomized Study of Donepezil Hydrochloride in Patients Who Have Undergone Partial- or Whole-Brain Irradiation for Brain Tumors Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CCCWFU-91105, WFU 91105°, NCT00369785, WFU-91105
12.	Phase III Randomized Study of Soy Protein/Isoflavones and Venlafaxine on Vasomotor Symptoms in Patients With Prostate Cancer Undergoing Hormonal Manipulation Phase: Phase III Type: Supportive care Status: Closed Age: 21 and over Sponsor: NCI Protocol IDs: CCCWFU-97405, CCCWFU 97405, WFU-97405, CCCWFU-BG05-529, NCT00354432
13.	Phase III Randomized Study of APF530 Versus Palonosetron Hydrochloride in Combination With Dexamethasone For Prophylaxis of Acute- and Delayed-Onset, Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Undergoing Moderately or Highly Emetogenic Chemotherapy. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: APP-C2006-01, NCT00343460
14.	Phase III Randomized Study of PR1 Leukemia Peptide Vaccine and Sargramostim (GM-CSF) in Patients With Acute Myeloid Leukemia in Remission. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VACCINE-PR1-104, UCCRC-14613B, NCT00454168
15.	Phase III Randomized Study of Adjuvant Therapy Comprising Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With Versus Without Bevacizumab in Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E5103, E5103, NCT00433511
16.	First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00504, E1105, CDR0000561762, U10CA021115, ECOG-E1105, NCT00520975
17.	Phase III Randomized Study of Pyridoxine Hydrochloride in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Capecitabine for Colorectal or Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CRCA-CCTC-CAPP-IT, EUDRACT-2004-000325-29, EU-20786, ISRCTN82842634, CCTC-CAPP-IT, CCLG-CAPP-IT, NCT00559858
18.	Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Phase: Phase III Type: Treatment Status: Completed Age: 13 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MK-8669-011, AP23573-07-302, NCT00538239
19.	Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12414, 2008-001087-36, NCT00692770
20.	Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC6521, 2007-007943-29, NCT00694382
21.	A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC10145, EudraCT 2007-003592-39, NCT00699517
22.	Letrozole in Treating Women With Primary Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: MA17R, CAN-NCIC-MA17R, CDR0000614819, NCT00754845
23.	Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MK-0683-088, 2008_525, NCT00773747
24.	Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D8480C00055, NCT00777153
25.	Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects Phase: Phase III Type: Prevention Status: Closed Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 107638, NCT00779766